![Peter Morch Eriksen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Morch Eriksen
Président chez
MONSENSO A/S
Fortune : 501 965 $ au 30/06/2026
Profil
Peter Morch Eriksen currently works at Dormicor ApS, as Chairman, MTIC, as Chairman, Monsenso A, as Chairman from 2022, FluoGuide A, as Chairman from 2021, Aptashape ApS, as Chairman, Netpris GmbH, as Director, PMEconsult, as Director from 2004, PME Holding ApS, as Managing Director & Director, Nervex AS, as Director, Bioporto, Inc., as Director, Bioporto Diagnostics, Inc., as Director, Veterinary Diagnostics A, as Director, and Reponex Pharmaceuticals A, as Director.
Mr. Eriksen also formerly worked at Brüel & Kjær North America, Inc., as Chief Executive Officer from 1992 to 1997, Bioporto Diagnostics A, as Chief Executive Officer & Director from 2013 to 2021, MedicoSelskabet September 2014 ApS, as Chief Executive Officer, PNN Medical A, as Chief Executive Officer from 2008 to 2009, Sense AS, as Chief Executive Officer from 2011 to 2013, Bioporto A, as Group Chief Executive Officer from 2024 to 2025, Pharma Equity Group A, as Chairman from 2022 to 2023, MedTech Innovation Center, as Chairman from 2008 to 2019, InnoCC ApS, as Chairman, JGN 1 3-12-2018 ApS, as Chairman, Ocumove ApS, as Chairman, Biostrip ApS, as Chairman from 2022 to 2023, MyBlueLabel Compliance Services A, as Chairman from 2022 to 2023, Vitrolife A, as Director from 2008 to 2010, Veterinary Diagnostics Institute, Inc., as Director, Online Grænsehandel Group ApS, as Director, Norma AS (Norway), as Director from 2011 to 2012, Medtronic, Inc., as Vice President & General Manager-Gastroenterology from 2002 to 2003, and Deltek Danmark A, as Chief Operational Officer from 1997 to 1998.
Mr. Eriksen received his undergraduate degree from Copenhagen Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FLUOGUIDE A/S 0,71 % | 31/12/2024 | 115 669 ( 0,71 % ) | 501 965 $ | 30/06/2026 |
Postes actifs de Peter Morch Eriksen
| Sociétés | Poste | Début |
|---|---|---|
| FLUOGUIDE A/S | Président | 09/02/2021 |
| MONSENSO A/S | Président | 01/04/2022 |
Reponex Pharmaceuticals A/S
 Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Directeur/Membre du Conseil | - |
Veterinary Diagnostics A/S | Directeur/Membre du Conseil | - |
Bioporto Diagnostics, Inc.
 Bioporto Diagnostics, Inc. Marine ShippingTransportation Bioporto Diagnostics, Inc. is a publicly traded in American vitro diagnostics company specializing in the development and commercialization of biomarker-based tests focused on acute kidney injury (AKI). The company is based in Chicago. The company’s flagship products utilize the NGAL (neutrophil gelatinase-associated lipocalin) biomarker to enable early risk assessment and diagnosis of AKI, including the NGAL Test™, a CE-marked diagnostic available internationally, and Pronephro AKI™, the first FDA-cleared biomarker test for pediatric AKI risk assessment, marketed through Roche Diagnostics. Bioporto also provides NGAL ELISA kits for preclinical and translational nephropathy research across multiple species, supporting drug development and nephrotoxicity studies. | Directeur/Membre du Conseil | - |
Bioporto, Inc. | Directeur/Membre du Conseil | - |
Nervex AS | Directeur/Membre du Conseil | - |
Netpris GmbH
 Netpris GmbH Food RetailRetail Trade Provides online food and beverage shopping services | Directeur/Membre du Conseil | - |
PME Holding ApS | Directeur Général | - |
| ░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Peter Morch Eriksen
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Peter Morch Eriksen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
85
Relations au 1er degré
32
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 32 |
|---|---|
Medtronic, Inc.
 Medtronic, Inc. Medical SpecialtiesHealth Technology Manufactures medical devices for hypertension care | Health Technology |
Deltek Danmark A/S (Denmark)
 Deltek Danmark A/S (Denmark) Packaged SoftwareTechnology Services Develops web-based software solutions | Technology Services |
Bioporto A/S
 Bioporto A/S Medical SpecialtiesHealth Technology Develops and markets human and animal neutrophil gelatinase-associated lipocalin antibodies kits | Health Technology |
Pharma Equity Group A/S
 Pharma Equity Group A/S Pharmaceuticals: MajorHealth Technology Functions as an investment holding company whose subsidiary develops bacterial peritonitis, chronic skin ulcers, inflammatory bowel and cancer biopharmaceuticals | Health Technology |
Copenhagen Business School
 Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dormicor ApS
 Dormicor ApS Medical SpecialtiesHealth Technology Develops solution for treatment of depression through intelligent sleep control | Health Technology |
Brüel & Kjær North America, Inc.
 Brüel & Kjær North America, Inc. Wholesale DistributorsDistribution Services Supplies instruments for measuring sound | Distribution Services |
Bioporto Diagnostics A/S
 Bioporto Diagnostics A/S BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
MedTech Innovation Center | |
MedicoSelskabet September 2014 ApS
 MedicoSelskabet September 2014 ApS Medical SpecialtiesHealth Technology Develops medical devices for cardiovascular sensing | Health Technology |
Vitrolife A/S
 Vitrolife A/S Industrial MachineryProducer Manufacturing Manufactures laboratory equipment and customizes software | Producer Manufacturing |
PNN Medical A/S | |
Veterinary Diagnostics Institute, Inc.
 Veterinary Diagnostics Institute, Inc. Medical/Nursing ServicesHealth Services Provides veterinary reference laboratory services and in-house diagnostic products | Health Services |
Netpris GmbH
Netpris GmbH Food RetailRetail Trade Provides online food and beverage shopping services | Retail Trade |
MTIC | |
PMEconsult | |
InnoCC ApS
 InnoCC ApS Medical SpecialtiesHealth Technology Provides monitoring equipment for people in a respirator | Health Technology |
Online Grænsehandel Group ApS | |
JGN 1 3-12-2018 ApS
 JGN 1 3-12-2018 ApS Medical SpecialtiesHealth Technology Develops and manufactures medical devices | Health Technology |
PME Holding ApS | |
Ocumove ApS
 Ocumove ApS Medical SpecialtiesHealth Technology Develops a medical device for use in sleep analysis on patients in medical treatment for depression | Health Technology |
Norma AS (Norway)
 Norma AS (Norway) Electronic ComponentsElectronic Technology Manufactures thermal Monocular | Electronic Technology |
Sense AS | |
Nervex AS | |
Monsenso A/S
 Monsenso A/S Internet Software/ServicesTechnology Services Provides mobile health solutions for mental health can help in the prevention, early intervention and treatment of mental illness or behavioral disorders | Technology Services |
FluoGuide A/S
 FluoGuide A/S Pharmaceuticals: MajorHealth Technology Engages in the development of drugs used for the improvement of surgical outcomes by making cancer fluorescent | Health Technology |
Bioporto, Inc. | |
Bioporto Diagnostics, Inc.
Bioporto Diagnostics, Inc. Marine ShippingTransportation Bioporto Diagnostics, Inc. is a publicly traded in American vitro diagnostics company specializing in the development and commercialization of biomarker-based tests focused on acute kidney injury (AKI). The company is based in Chicago. The company’s flagship products utilize the NGAL (neutrophil gelatinase-associated lipocalin) biomarker to enable early risk assessment and diagnosis of AKI, including the NGAL Test™, a CE-marked diagnostic available internationally, and Pronephro AKI™, the first FDA-cleared biomarker test for pediatric AKI risk assessment, marketed through Roche Diagnostics. Bioporto also provides NGAL ELISA kits for preclinical and translational nephropathy research across multiple species, supporting drug development and nephrotoxicity studies. | Transportation |
Veterinary Diagnostics A/S | |
Biostrip ApS | |
Reponex Pharmaceuticals A/S
Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
MyBlueLabel Compliance Services A/S
 MyBlueLabel Compliance Services A/S Packaged SoftwareTechnology Services Operates cloud-based management platform | Technology Services |
Choisissez Zonebourse 
